CROCE, Carlo Maria
 Distribuzione geografica
Continente #
NA - Nord America 17.725
AS - Asia 3.752
EU - Europa 3.658
SA - Sud America 266
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
Totale 25.426
Nazione #
US - Stati Uniti d'America 17.690
CN - Cina 1.445
SG - Singapore 1.414
UA - Ucraina 998
TR - Turchia 600
DE - Germania 597
IT - Italia 569
GB - Regno Unito 427
PL - Polonia 345
BR - Brasile 246
SE - Svezia 245
FI - Finlandia 232
VN - Vietnam 96
ID - Indonesia 74
FR - Francia 69
NL - Olanda 42
RU - Federazione Russa 40
BE - Belgio 33
HK - Hong Kong 27
CA - Canada 26
AT - Austria 25
IR - Iran 17
IN - India 15
KR - Corea 13
IQ - Iraq 8
AR - Argentina 7
CZ - Repubblica Ceca 7
JP - Giappone 7
UZ - Uzbekistan 7
PK - Pakistan 6
GR - Grecia 5
LT - Lituania 5
RO - Romania 5
AU - Australia 4
EU - Europa 4
MA - Marocco 4
MX - Messico 4
BD - Bangladesh 3
ES - Italia 3
IE - Irlanda 3
MY - Malesia 3
NP - Nepal 3
PE - Perù 3
TW - Taiwan 3
VE - Venezuela 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CH - Svizzera 2
CO - Colombia 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
OM - Oman 2
RS - Serbia 2
SS - ???statistics.table.value.countryCode.SS??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
HN - Honduras 1
IM - Isola di Man 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
MD - Moldavia 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PS - Palestinian Territory 1
TN - Tunisia 1
UY - Uruguay 1
Totale 25.426
Città #
Fairfield 2.681
Woodbridge 2.480
Houston 1.559
Ashburn 1.246
Jacksonville 1.139
Seattle 1.049
Chandler 991
Ann Arbor 892
Wilmington 877
Cambridge 857
Santa Clara 643
Singapore 601
Izmir 412
Warsaw 341
Nanjing 334
Princeton 251
San Diego 231
Beijing 215
Boardman 194
Ferrara 147
Addison 121
Milan 112
Los Angeles 101
Dong Ket 96
Nanchang 94
Shanghai 93
Shenyang 91
New York 81
Dearborn 76
Jakarta 72
Hebei 68
Mountain View 59
Tianjin 59
Jinan 56
Bremen 55
Jiaxing 53
Changsha 42
Falls Church 40
Kunming 40
London 40
Redwood City 39
Norwalk 35
San Mateo 35
Hangzhou 32
Zhengzhou 32
Brussels 31
Guangzhou 28
Tappahannock 28
Hong Kong 27
Orange 27
Munich 26
Ningbo 26
Des Moines 25
Verona 24
Auburn Hills 23
Nuremberg 22
Taizhou 22
Falkenstein 21
Washington 21
Hefei 19
Philadelphia 18
Helsinki 15
Toronto 15
Chicago 14
Indiana 14
Lanzhou 13
Rome 13
Vienna 13
São Paulo 12
Augusta 11
Bologna 11
Changchun 11
Frankfurt am Main 9
Hounslow 9
Redmond 9
Rio de Janeiro 9
Kilburn 7
Monmouth Junction 7
Ottawa 7
Padova 7
Tashkent 7
Amsterdam 6
Cagliari 6
Leawood 6
Naples 6
Ardabil 5
Berkeley 5
Istanbul 5
Napoli 5
Tallahassee 5
Belo Horizonte 4
Brno 4
Casalecchio Di Reno 4
Council Bluffs 4
Curitiba 4
Guiyang 4
Haikou 4
Juiz de Fora 4
Mauá 4
Palermo 4
Totale 19.452
Nome #
Anti-miR-135b in colon cancer treatment: Results from a preclinical study. 249
Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model 191
Loss of miR-204 expression is a key event in melanoma 186
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 183
The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. 178
miRNA signatures associate with pathogenesis and progression of osteosarcoma. 172
miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells 170
13q14 deletions in chronic lymphoproliferative disorders with the t(11;14)(q13;q32): a cytogenetic and interphase cytogenetic study. 169
13q14 deletion in non-Hodgkin's lymphoma: Correlation with clinicopathologic features 169
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. 165
MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia 165
MicroRNA e cancro 165
miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia 162
Identification of microRNA activity by Targets' Reverse EXpression. 160
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis 159
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 159
Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors 158
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. 156
p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. 153
MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin 153
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer 152
A novel t(9;11)(p22;q23) with ALL-1 gene rearrangement associated with progression of a myeloproliferative disorder to acute myeloid leukemia 151
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. 151
The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. 151
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells 151
miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. 148
MicroRNA involvement in hepatocellular carcinoma 147
MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma 147
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 147
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer 145
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer 145
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML 143
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells 141
Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study 140
Transcriptional map of 170-kb region at chromosome 11p15.5: Identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples 140
null 139
MicroRNA expression profiling in human Barrett's carcinogenesis. 139
Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. 137
Knockout mice reveal a tumor suppressor function for Testin 136
Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a 135
Anti-miR-135b in colon cancer treatment: Results from a preclinical study. 135
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues 135
A microRNA DNA methylation signature for human cancer metastasis 134
MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC 134
B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice 134
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer 133
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF- α stimulation and their possible roles in regulating the response to endotoxin shock 133
null 132
Tumor suppressor functions of ARLTS1 in lung cancers 132
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2 131
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. 131
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis 131
ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias 130
MicroRNA genes are frequently located near mouse cancer susceptibility loci 130
microRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer 130
Reprogramming of miRNA networks in cancer and leukemia 129
null 128
null 128
A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention 127
MiR-145 participates with TP53 in a death promoting regulatory loop and targets estrogen receptor in human breast cancer cells 127
null 127
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer 126
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. 126
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. 126
A microRNA signature of hypoxia 126
Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. 124
WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function 123
null 122
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia 122
A microRNA signature for a BMP2-induced osteoblast lineage commitment program 122
Significance of Aberrant Expression of MicroRNAs in Cancer Cells 121
Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD 121
MicroRNA deregulation in human thyroid papillary carcinomas 121
Extensive modulation of a set of microRNAs in primary glioblastoma 120
Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas 120
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer 120
null 119
MicroRNAs 221 and 222 bypass quiescence and compromise cell survival 118
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality 118
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers 117
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma 117
null 116
The role of microRNA genes in papillary thyroid carcinoma 116
Oncogenic role of miR-483-3p at the IGF2/483 locus 116
TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos 115
Functional Implications of MicroRNAs in Acute Myeloid Leukemia by Integrating MicroRNA and Messenger RNA Expression Profiling 115
Mammalian microRNAs: a small world for fine-tuning gene expression 115
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 115
Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis 114
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia 114
Investigations on microRNAs in human chronic lymphocytic leukemia and control of cancer-associated molecular pathways 113
microRNA involvement in hepatocellular carcinoma 113
WWOX and p53 dysregulation synergize to drive the development of osteosarcoma 113
The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism 113
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer 113
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas 112
MicroRNA-135b promotes cancer progression acting as a downstream effector of oncogenic pathways in colon cancer 112
Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells 112
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells 112
Micro-RNA profiling in kidney and bladder cancers 111
Totale 13.647
Categoria #
all - tutte 118.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 996
Totale 119.366


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.382 0 0 0 0 0 0 0 0 527 519 197 139
2020/20213.520 274 369 191 408 211 340 155 389 98 406 401 278
2021/20222.731 124 318 263 67 95 108 151 135 80 201 287 902
2022/20232.423 249 98 61 306 380 391 103 259 323 19 131 103
2023/20241.074 126 169 60 38 79 182 32 69 23 18 30 248
2024/20252.932 144 94 387 137 585 360 160 283 782 0 0 0
Totale 25.749